Neutrophil-Lymphocyte Ratio Connected to Treatment Options and Inflammation Markers of Ankylosing Spondylitis

Basit Öğe Kaydı
dc.authoridguven, mustafa/0000-0001-8643-9775
dc.authoridAras, Adem Bozkurt/0000-0002-0140-5224
dc.contributor.authorGokmen, Ferhat
dc.contributor.authorAkbal, Ayla
dc.contributor.authorResorlu, Hatice
dc.contributor.authorGokmen, Esra
dc.contributor.authorGuven, Mustafa
dc.contributor.authorAras, Adem Bozkurt
dc.contributor.authorErbag, Gokhan
dc.date.accessioned2025-01-27T20:23:14Z
dc.date.available2025-01-27T20:23:14Z
dc.date.issued2015
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackgroundIn recent years, white blood cells (WBCs) and their subtypes have been studied in relation to inflammation. The aim of our study was to assess the relationship between neutrophil-lymphocyte ratio (NLR) and ankylosing spondylitis (AS). Materials and methodsWe enrolled a total of 177 patients, 96 AS and 81 healthy controls. Complete blood count, WBC, neutrophil and lymphocyte levels were measured, and the NLR was calculated. In the assessment of AS, we used the erythrocyte sedimentation rate, C-reactive protein (CRP), the Bath Ankylosing Spondylitis Disease Activity Index, and the Bath Ankylosing Spondylitis Functional Index. ResultsIn the present study, 96 AS and 81 healthy individuals were enrolled. The mean age was 43.8 12.9 and 46.5 +/- 11.2 years, respectively. Mean disease duration of AS patients was 6.9 +/- 5.6 years (median = 5, min-max = 1-25). The patients with AS had a higher NLR than the control individuals (mean NLR, 2.24 +/- 1.23 and 1.73 +/- 0.70, respectively, P < 0.001). A statistically significant positive correlation was observed between NLR and CRP (r = 0.322, P = 0.01). The patients receiving antitumor necrosis factor therapy had a lower NLR than the patients receiving nonsteroidal anti-inflammatory drug therapy (mean NLR, 1.71 +/- 0.62 and 2.41 +/- 1.33, respectively, P = 0.02). ConclusionNLR may be seen as a useful marker for demonstrating inflammation together with acute phase reactants such as CRP and in evaluating the effectiveness of anti-TNF- therapy.
dc.identifier.doi10.1002/jcla.21768
dc.identifier.endpage298
dc.identifier.issn0887-8013
dc.identifier.issn1098-2825
dc.identifier.issue4
dc.identifier.pmid24849656
dc.identifier.scopus2-s2.0-84937119794
dc.identifier.scopusqualityQ1
dc.identifier.startpage294
dc.identifier.urihttps://doi.org/10.1002/jcla.21768
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22152
dc.identifier.volume29
dc.identifier.wosWOS:000358250300009
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal of Clinical Laboratory Analysis
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectankylosing spondylitis
dc.subjectneutrophil-lymphocyte ratio
dc.subjectacute phase reactants
dc.subjectanti-TNF-alpha
dc.titleNeutrophil-Lymphocyte Ratio Connected to Treatment Options and Inflammation Markers of Ankylosing Spondylitis
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu